Skip to main content

Oppenheimer Reaffirms Their Buy Rating on Legend Biotech (LEGN)

Tipranks - Tipranks - Sat Mar 7, 7:02AM CST

Oppenheimer analyst Kostas Biliouris reiterated a Buy rating on Legend Biotech today and set a price target of $75.00.

Claim 70% Off TipRanks Premium

Biliouris covers the Healthcare sector, focusing on stocks such as Legend Biotech, Alnylam Pharma, and Sarepta Therapeutics. According to TipRanks, Biliouris has an average return of -1.2% and a 40.07% success rate on recommended stocks.

In a report released on February 24, H.C. Wainwright also reiterated a Buy rating on the stock with a $50.00 price target.

See today’s best-performing stocks on TipRanks >>

Based on Legend Biotech’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $272.33 million and a GAAP net loss of $39.69 million. In comparison, last year the company earned a revenue of $160.21 million and had a GAAP net loss of $125.32 million

Read More on LEGN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).